TL1A in IBD: Why the Whole Field Suddenly Cares About One Ligand
Targets move in and out of fashion in drug development. Usually the enthusiasm shows up before the biology has earned it. TL1A in IBD is one of the cases where it ran the other way. The science got convincing first, and the money came chasing it. When Merck paid $10.8 billion for Prometheus Biosciences in […]
TL1A in IBD: Why the Whole Field Suddenly Cares About One Ligand Read More »